EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy
- 15 December 2009
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 2 (101), ra82
- https://doi.org/10.1126/scisignal.2000446
Abstract
Inhibitors of fatty acid signaling promote apoptosis in glioblastoma cells with highly active EGFR signaling.Keywords
This publication has 39 references indexed in Scilit:
- The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesisProceedings of the National Academy of Sciences of the United States of America, 2009
- Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate CancerJNCI Journal of the National Cancer Institute, 2009
- Tumours with PI3K activation are resistant to dietary restrictionNature, 2009
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell GrowthCell Metabolism, 2008
- Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase ActivityCancer Cell, 2008
- Regulation of Sterol Synthesis in EukaryotesAnnual Review of Genetics, 2007
- Orphan nuclear receptor estrogen-related receptor α is essential for adaptive thermogenesisProceedings of the National Academy of Sciences of the United States of America, 2007
- The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005